natgillin/translations-raw huggingface dataset:
It is not recommended to coadminister efavirenz and Nevirapine Teva (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1).
Ne preporučuje se istodobna primjena efavirenza i Nevirapin Teva (vidjeti dio 4.4.) zbog dodatne toksičnosti i izostanka koristi u odnosu na sam NNRTI (za rezultate 2NN ispitivanja, vidjeti dio 5.1).
You may take Nevirapine Teva with or without food.
Možete uzimati Nevirapin Teva s hranom ili bez nje.
Nevirapine Teva should not be used as the sole active antiretroviral, as monotherapy with any antiretroviral has shown to result in viral resistance.
Nevirapin Teva se ne smije primjenjivati kao monoterapija aktivnim antiretrovirusnim lijekom, jer monoterapija bilo kojim antiretrovirusnim lijekom rezultira virusnom rezistencijom.
Only a small fraction (< 5 %) of the radioactivity in urine (representing < 3 % of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Samo mali dio (< 5%) radioaktivnosti u urinu (koji predstavlja <3% ukupne doze)
Clinical hepatitis reported as clinical adverse event occurred in 10 (2.6%) and 2 (0.5%) patients in the nevirapine twice daily and efavirenz groups respectively.
Klinički hepatitis prijavljen kao klinička nuspojava dogodio se u 10 (2,6%) bolesnika na nevirapinu dvaput dnevno i u 2 (0,5%) bolesnika na efavirenzu.
Nevirapine Cmax ↑ 1.24 compared to historical controls.
Nevirapin Cmax ↑ 1,24 u usporedbi s povijesnom kontrolom.
The double non-nucleoside study 2 NN was a randomised, open-label, multicentre prospective study comparing the NNRTIs nevirapine, efavirenz and both medicinal products given together.
2 NN studija dvostrukih nenukleozida je randomizirana, otvorena, multicentrična, prospektivna studija u kojoj su uspoređena dva NNRTI-a - nevirapin i efavirenz - kao monoterapija u odnosu na kombinaciju.
Nevirapine Teva may be taken with or without food.
Nevirapin Teva se može uzimati s hranom ili bez nje.
The predetermined primary efficacy comparison was between the nevirapine twice daily and the efavirenz treatment groups.
Predodređena primarna djelotvornost liječenih skupina bila je uspoređena između nevirapina dvaput dnevno i efavirenza.
Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities.
Osipi su obično blage do umjerene makulopapularno eritematozno izbijanje kožnih promjena, s ili bez svrbeža, na trupu, licu i ekstremitetima.
If patients present with a suspected nevirapine-associated rash, liver function tests should be performed.
Ako se u bolesnika sumnja na osip povezan s nevirapinom, moraju se učiniti testovi jetrene funkcije.
Results of a 48-week analysis of the South African study BI 1100.1368 confirmed that the 4/7 mg/kg and 150 mg/m2 nevirapine dose groups were well tolerated and effective in treating antiretroviral naive paediatric patients.
Pedijatrijska populacija Rezultati analize studije BI 1100.1368 provedene u Južnoj Africi, potvrdili su da se doze nevirapina od 4/7 mg/kg i 150 mg/m2 dobro podnose i da su učinkovite u liječenju prethodno neliječenih pedijatrijskih bolesnika.
Post-Exposure-Prophylaxis: Serious hepatotoxicity, including liver failure requiring transplantation, has been reported in HIV-uninfected individuals receiving multiple doses of nevirapine in the setting of post-exposure-prophylaxis (PEP), an unapproved use.
Postekspozicijska profilaksa: Teška hepatotoksičnost, uključujući zatajenje jetre koje zahtijeva transplataciju, prijavljena je u osoba koje nisu inficirane HIV-om, a koje su primale višekratne doze nevirapina u svrhu postekspozicijske profilakse (PEP), što nije odobrena indikacija primjene.
- St John's Wort (Hypericum perforatum, medicine to treat depression) - rifampicin (medicine to treat tuberculosis) - rifabutin (medicine to treat tuberculosis) - macrolides e.g. clarithromycin (medicine to treat bacterial infections) - fluconazole (medicine to treat fungal infections) - ketoconazole (medicine to treat fungal infections) - itraconazole (medicine to treat fungal infections) - methadone (medicine used for treatment of opiate addicts) - warfarin (medicine to reduce blood clotting) - hormonal contraceptives (e.g. the “pill”) - atazanavir (another medicine to treat HIV-infection) - lopinavir/ritonavir (another medicine to treat HIV-infection) - fosamprenavir (another medicine to treat HIV-infection) - efavirenz (another medicine to treat HIV-infection) - etravirine (another medicine to treat HIV-infection) - rilpivirine (another medicine to treat HIV-infection) - delavirdine (another medicine to treat HIV-infection) - zidovudine (another medicine to treat HIV-infection) - boceprevir (medicine to treat hepatitis C) - telaprevir (medicine to treat hepatitis C) - elvitegravir/cobicistat (another medicine to treat HIV-infection)
- atazanavir (drugi lijek za liječenje HIV infekcije) - lopinavir/ritonavir (drugi lijek za liječenje HIV infekcije) - fosamprenavir (drugi lijek za liječenje HIV infekcije) - efavirenz (drugi lijek za liječenje HIV infekcije) - etravirin (drugi lijek za liječenje HIV infekcije) - rilpivirin (drugi lijek za liječenje HIV infekcije) - delavirdin (drugi lijek za liječenje HIV infekcije) - zidovudin (drugi lijek za liječenje HIV infekcije) - boceprevir (lijek za liječenje hepatitisa C) - telaprevir (lijek za liječenje hepatitisa C) - elvitegravir/kobicistat (drugi lijek za liječenje HIV infekcije)
Treatment initiation pack
Pakovanje za početak liječenja
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Također su prijavljeni autoimuni poremećaji (kao što su Gravesova bolest i autoimuni hepatits); međutim, vrijeme do nastupa varira te može proći više mjeseci od početka liječenja do njihove pojave (vidjeti dio 4.4.).
Of the patients with grade 3 or 4 liver-associated laboratory toxicity, the proportions coinfected with hepatitis B or hepatitis C virus were 6.7% and 20.0% in the nevirapine twice daily group, 5.6% and 11.1% in the efavirenz group.
Među bolesnicima koji su imali laboratorijske nalaze oštećenja jetre stupnja 3 ili 4, udio onih koji su bili istodobno inficirani s virusom hepatitisa B ili C bio je 6,7% odnosno 20,0% u skupini koja je dobivala nevirapin dvaput dnevno, odnosno 5,6% i 11,1% u skupini koja je dobivala efavirenz.
Coadministration with herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine (see section 4.5).
Istodobna primjena s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) zbog rizika od smanjenja koncentracija u plazmi te smanjenih kliničkih učinaka nevirapina (vidjeti dio 4.5.).
Nevirapine in combination with efavirenz exhibited a strong antagonistic anti-HIV-1 activity in vitro (see section 4.5) and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide.
In vitro, nevirapin u kombinacji s efavirenzom pokazuje snažni antagonizam anti-HIV-1-aktivnosti (vidjeti dio 4.5.) te s inhibitorom proteaza ritonavirom ili inhibitorom fuzije enfurvitidom rezultira aditivnim do antagonističkim učinkom.
Tell your doctor immediately if you experience rash and any of the other side effects of a hypersensitivity (allergic) reaction.
Odmah obavijestite liječnika ako dobijete osip ili neku drugu nuspojavu reakcije preosjetljivosti
Data reported in the literature from 20 HIV-infected patients suggest a steady state Cmax of 5.74 μg/ml (5.00-7.44) and Cmin of 3.73 μg/ml (3.20-5.08) with an AUC of 109.0 h*μg/ml (96.0-143.5) in patients taking 200 mg of nevirapine bid.
om inficiranih bolesnika ukazuju na stanje dinamičke ravnoteže Cmax od 5,74 µg/ml (5,00-7,44) i Cmin od 3,73 µg/ml (3,20-5,08) te AUC od 109,0 h*μg/ml (96,0-143,5) u bolesnika koji uzimaju 200 mg nevirapina dvaput dnevno.
Patients who participated in the 2NN study and were still under active follow-up at week 48 when the study closed and were still being treated at the study clinic, were asked to participate in this study.
2NN ispitivanja, kada je ispitivanje završeno, još uvijek bili pod aktivnim praćenjem, te su nastavili liječenje u klinici uključenoj u studiju.
Investigations Common liver function tests abnormal (alanine aminotransferase increased; transaminases increased; aspartate aminotransferase increased; gamma-glutamyltransferase increased; hepatic enzyme increased; hypertransaminasaemia) Uncommon blood phosphorus decreased; blood pressure increased
Često abnormalni testovi jetrene funkcije (povišena alanin-aminotransferaza, povišene transaminaze; povišena aspartat-aminotransferaza; povišena gamaglutamiltransferaza; povišeni jetreni enzimi; hipertransaminazemija)
Genotypic analysis of isolates from antiretroviral naïve patients experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine for 48 weeks showed that isolates from 8/25 and 23/46 patients, respectively, contained one or more of the following NNRTI resistance-associated substitutions:
Genotipska analiza izolata dobivenih od bolesnika prethodno neliječenih, a dobili su virološki neuspjeh (n=71) liječenja nevirapinom jednom dnevno (n=25) ili dvaput dnevno (n=46) u kombinaciji s lamivudinom i stavudinom tijekom 48 tjedana, pokazala je da su izolati iz 8/25 odnosno 23/46
Nevirapine Teva administration above the recommended dose might increase the frequency and seriousness of skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Primjena Nevirapina Teva u dozama iznad preporučenih može povećati učestalost i ozbiljnost kožnih reakcija, kao što su Stevens-Johnsonov sindrom i toksična epidermalna nekroliza.
If you forget to take Nevirapine Teva
Ako ste zaboravili uzeti Nevirapin Teva
Therefore, caution should be recommended when driving a car or operating machinery.
Stoga se preporuča oprez prilikom upravljanja vozilima i rada na strojevima.
ANTI-INFECTIVES Antiretrovirals
ANTIMIKROBNI LIJEKOVI Antiretrovirusni lijekovi
The study randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one PI and whose plasma HIV-1 RNA levels had been less than 200 c/ml for at least the previous six months to switch from the PI to nevirapine (155 patients), efavirenz (156), or abacavir (149).
Uključeno je 460 odraslih koji su prethodno uzimali dva nukelozidna inhibitora reverzne transkriptaze i najmanje jedan inhibitor proteaza i koji su tijekom najmanje 6 prethodnih mjeseci imali razine HIV-1 RNK <200 kopija/ml te su prebačeni na nevirapin (155 bolesnika), efarvirenz (156) ili abakavir (149).
The proportion of patients with at least one grade 3 or 4 liver-associated laboratory toxicity was 8.3% for nevirapine twice daily and 4.5% for efavirenz.
Udio bolesnika s najmanje jednim laboratorijskim nalazom povezanim s oštećenjem jetre stupnja 3 ili 4 bio je 8,3% za nevirapin primjenjen dvaput dnevno, a 4,5% za efavirenz.
The most frequently reported adverse reactions related to nevirapine therapy, across all clinical studies, were rash, allergic reactions, hepatitis, abnormal liver function tests, nausea, vomiting, diarrhoea, abdominal pain, fatigue, fever, headache and myalgia.
Najčešće prijavljene nuspojave povezane s terapijom nevirapinom u svim kliničkim studijama bile su osip, alergijske reakcije, hepatitis, abnormalni nalazi testova jetrene funkcije, mučnina, povraćanje, proljev, bol u abdomenu, umor, vrućica, glavobolja i mijalgija.
Package leaflet: Information for the patient Nevirapine Teva 200 mg tablets nevirapine
Uputa o lijeku: Informacija za bolesnika Nevirapin Teva 200 mg tablete nevirapin
Nevirapine concentrations not measured, no effect is expected.
Koncentracije nevirapina nisu mjerene,
Nevirapine AUC ↓ 0.42
Nevirapin AUC ↓ 0,42
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČI ODGOVORNI ZA ZA PUŠTANJE SERIJE
Metabolite 14-OH clarithromycin
Metabolit 14-OH klaritromicin AUC Metabolit 14-OH klaritromicin Cmin Metabolit 14-OH klaritromicin Cmax
4.7 Effects on ability to drive and use machines
Utjecaj na sposobnost upravljanja vozilima i rada na strojevima
Women of childbearing potential should not use oral contraceptives as the sole method for birth control, since nevirapine might lower the plasma concentrations of these medicinal products (see sections 4.4 & 4.5).
U žena reproduktivne dobi oralni kontraceptivi ne smiju se primjenjivati kao jedina metoda kontrole začeća jer nevirapin može sniziti koncentracije tih lijekova u plazmi (vidjeti dijelove 4.4. i 4.5.).
The primary endpoint, treatment failure, was defined as less than 1 log10 decline in plasma HIV-1 RNA in the first 12 weeks, or two consecutive measurements of more than 50 copies/ ml from week 24 onwards, or disease progression.
Primarni ishod, terapijski neuspjeh, definiran je kao sniženje plazmatske razine HIV-1 RNK tijekom prvih 12 tjedana ili nalaza dva uzastopna mjerenja koja pokazuju više od 50 kopija/ml nakon 24
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Autoimuni poremećaji (kao što su Gravesova bolest i autoimuni hepatits) također su prijavljeni u postupku imune reaktivacije; međutim, vrijeme do nastupa varira te može proći više mjeseci od početka liječenja do njihove pojave.
What you need to know before you take Nevirapine Teva Do not take Nevirapine Teva
Što morate znati prije nego počnete uzimati Nevirapin Teva
- reduces the chances of your HIV infection becoming resistant to your antiretroviral medicines.
- uvelike povećava učinkovitost kombinacije antiretrovirusnih lijekova. - smanjuje vjerojatnost da HIV infekcija postane otporna na antiretrovirusne lijekove koje uzimate.
The use of nevirapine has not been evaluated within a specific study on PEP, especially in term of treatment duration and therefore, is strongly discouraged.
Ne postoje posebne studije o primjeni nevirapina u indikaciji PEP-a, osobito u smislu trajanja liječenja, te se stoga takva primjena izričito ne preporučuje.
A reduction in red blood cells (anaemia), which may be related to nevirapine therapy, is also more commonly observed in children.
Smanjenje broja crvenih krvnih stanica (anemija), koje može biti povezano s terapijom nevirapinom,
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection (AIDS defining illness), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
U nekih bolesnika s uznapredovalom HIV infekcijom (AIDS) i anamnezom oportunističkih infekcija (bolest koja se definira kao AIDS), ubrzo nakon početka liječenja lijekovima protiv HIV-a mogu se pojaviti znakovi i simptomi upale uzrokovani prethodnim infekcijama.
Immune Reactivation Syndrome: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Sindrom imonoreaktivacije: U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme započinjanja kombinirane antiretrovirusne terapije (CART) može se pojaviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te izazvati ozbiljno kliničko stanje ili pogoršanje simptoma.
Nevirapine Teva 200 mg
Nevirapin Teva 200 mg
The frequencies estimated are based on pooled clinical study data for adverse reactions considered related to nevirapine treatment.
Procjena učestalosti temelji se na objedinjenim podacima iz kliničkih ispitivanja o nuspojavama za koje se smatra da su povezane s liječenjem nevirapinom.
You should not use Nevirapine Teva on its own.
Nevirapin Teva se ne smije primjenjivati sam.
No specific drug-drug interaction study has been performed.
Nisu provedena specifična interakcijska ispitivanja.
Nevirapine Cmin ↓ 0.32
Nevirapin Cmin ↓ 0,32
Nevirapine Teva contains lactose
Nevirapin Teva sadrži laktozu
Furthermore, combining the following compounds with Nevirapine Teva is not recommended: efavirenz, ketoconazole, delavirdine, etravirine, rilpivirine, elvitegravir (in combination with cobicistat), atazanavir (in combination with ritonavir), boceprevir; fosamprenavir (if not co-administered with low dose ritonavir) (see section 4.5).
ketokonazol, delavirdin, etravirin, rilpivirin, elvitegravir (u kombinaciji s kobicistatom), atazanavir (u kombinaciji s ritonavirom), boceprevir, fosamprenavir (ako se primjenjuje istovremeno uz nisku dozu ritonavira) (vidjeti dio 4.5).
If you stop taking Nevirapine Teva
Ako prestanete uzimati Nevirapin Teva
Hepatic dysfunction: A steady state study comparing 46 patients with mild (n=17: Ishak Score 1-2), moderate (n=20; Ishak Score 3-4), or severe (n=9; Ishak Score 5-6, Child-Pugh A in 8 pts., for 1 Child-Pugh score not applicable) liver fibrosis as a measure of hepatic impairment was conducted.
Disfunkcija jetre: Provedeno je ispitivanje u stanju dinamičke ravnoteže u 46 bolesnika s blagom (n=17; Ishak indeks 1-2), umjerenom (n=20; Ishak indeks 3-4), ili teškom (n=9; Ishak indeks 5-6, Child Pugh A u 8 bolesnika, za jednoga Child Pugh indeks nije primjenjiv)
Patients should be instructed that a major toxicity of nevirapine is rash.
Bolesnike je potrebno upozoriti da je osip važna manifestacija toksičnosti nevirapina.
Therefore coadministration would likely result in altered plasma levels of cobicistat and Nevirapine Teva.
Stoga bi istodobna primjena vjerojatno rezultirala promijenjenim vrijednostima kobicistata i Nevirapina Teva u plazmi.
Check with your doctor or pharmacist if you are not sure.
Uvijek uzimajte ovaj lijek točno onako kako Vam je rekao liječnik Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni.
Nevirapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Nevirapin je kontraindiciran u bolesnika s teškim jetrenim poremećajima (Child-Pugh C, vidjeti dio 4.3.).
Caution should be exercised when prescribing nevirapine to pregnant women (see section 4.4).
Stoga je nužan oprez u propisivanju nevirapina trudnicama (vidjeti dio 4.4.).
Nevirapine Teva should be administered by physicians who are experienced in the treatment of HIV infection.
Nevirapin Teva moraju primjenjivati liječnici s iskustvom u liječenju HIV-infekcije.
Oral hormonal contraceptives should not be used as the sole method of contraception in women taking Nevirapine Teva (see section 4.4).
Oralni hormonski kontraceptivi ne smiju se primjenjivati kao jedina metoda kontracepcije u žena koje uzimaju Nevirapin Teva (vidjeti dio
At 12 months, the Kaplan-Meier estimates of the likelihood of reaching the endpoint were 10 % in the nevirapine group, 6 % in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis).
Vjerojatnost postizanja primarnog ishoda nakon 12 mjeseci liječenja, procjena po Kaplan-Meieru, bila je 10% za nevirapin, 6% za efavirenz i 13% za abakavir (p=0,10 prema ITT analizi).
Nevirapine co-administration did not alter the ovulation suppression effects of DMPA.
Istodobna primjena nevirapina nije promijenila učinke ovulacijske supresije DMPA.
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin, rifampicin, and trimethoprim/sulfamethoxazole.
Metaboliti nevirapina: Ispitivanja na mikrosomima ljudske jetre pokazale su da dapson, rifabutin, rifampicin i trimetroprim/sulfametoksazol nisu utjecali na stvaranje hidroksiliranih metabolita nevirapina, dok su ketokonazol i eritromicin značajno inhibirali njihovo stvaranje.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Lijek se izdaje na ograničeni recept. (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
Fertility In reproductive toxicology studies, evidence of impaired fertility was seen in rats.
U ispitivanjima reproduktivne toksičnosti kod štakora su uočeni poremećaji plodnosti.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
kopija/ml primali su nevirapin 400 mg jednom dnevno, nevirapin 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili nevirapin (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Nevirapine Teva dose increased until the rash has resolved.
Na što treba paziti u doziranju Bolesnicima kod kojih se tijekom 14-dnevnog uvodnog razdoblja uz dozu od 200 mg/dan pojavi osip ne smiju povećavati dozu Nevirapina Teva dok se osip ne povuče.
These events are commonly associated with other antiretroviral agents and may be expected to occur when Nevirapine Teva is used in combination with other agents; however, it is unlikely that these events are due to treatment with Nevirapine Teva.
Ovi slučajevi često se vežu za druge antiretrovirusne lijekove te se njihova pojava može očekivati kada se Nevirapin Teva primjenjuje u kombinaciji s drugim lijekovima; međutim, ne čini se da su ovakvi slučajevi uzrokovani liječenjem Nevirapinom Teva.
Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Nevirapin pripada skupini lijekova koji djeluju protiv virusa humane imunodeficijencije (HIV), a zovu se nenukleozidni inhibitori reverzne transkriptaze (NNRTI).
Enfuvirtide
Enfuvirtid
You should stop breast-feeding if you are taking Nevirapine Teva.
Potrebno je prekinuti dojenje ako uzimate Nevirapin Teva.
It allows continued monitoring of the benefit/risk balance of the medicinal product.
Time se omogućuje kontinuirano praćenje omjera koristi i rizika tog lijeka.
How to take Nevirapine Teva
Kako uzimati Nevirapin Teva
Reporting suspected adverse reactions after authorisation of the medicinal product is important.
Nakon odobrenja lijeka, važno je prijavljivanje sumnji na njegove nuspojave.
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts < 400 cells/mm3).
Povećan rizik primijećen je u muškaraca s detektabilnom HIV-1 RNK u plazmi i brojem CD4 >400 stanica/mm3 (6,3% naspram
If a patient is already taking St. John‘s Wort check nevirapine and if possible viral levels and stop St John‘s Wort.
Ako bolesnik već uzima gospinu travu, valja provjeriti koncentracije nevirapina i ako je moguće broj virusnih razina te prekinuti primjenu gospine trave.
- if you have taken Nevirapine Teva before and had to stop the treatment because you suffered from: - severe skin rash - skin rash with other symptoms for example: - fever - blistering - mouth sores - inflammation of the eye - swelling of the face - general swelling - shortness of breath
- ako ste prije uzimali Nevirapin Teva te ste morali prekinuti liječenje jer ste patili od: - teškog kožnog osipa - kožnog osipa s drugim simptomima, na primjer:
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
C koji se liječe kombiniranom antiretrovirusnom terapijom su pod povećanim rizikom od teških i potencijalno fatalnih jetrenih nuspojava.
For patients with renal dysfunction requiring dialysis an additional 200 mg dose of nevirapine following each dialysis treatment is recommended.
Za bolesnike s bubrežnom disfunkcijom koja zahtijeva dijalizu, preporučuje se dodatna doza od 200